Aster DM Healthcare Ltd. (ASTERDM) AI Stock Analysis

• Market Cap: ₹324.99B
• Dividend Yield: 0.84%
• Average Volume (3M): 57.99K
• Price to Earnings (P/E): 152.0
• Beta (1Y): 0.34
• Revenue Growth: -36.14%
• EPS Growth: -93.99%
• Country: IN
• Employees: 14,016
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 1.00
• Shares Outstanding: 518,121,030
• 10 Day Avg. Volume: 86,592
• 30 Day Avg. Volume: 57,995
• PEG Ratio: 0.52
• Price to Book (P/B): 122.33
• Price to Sales (P/S): 101.33
• P/FCF Ratio: 5.31K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 7.43
• Revenue Forecast (FY): ₹46.59B

• Rating: 62 Neutral
• Price Target: ₹665.00 ▲(8.09% Upside)
• Action: Downgraded Date: 10/23/25
• Date: Action: Downgraded 10/23/25

Aster DM Healthcare Ltd. has a solid financial foundation with strong profitability and effective equity utilization. However, the high P/E ratio suggests overvaluation, and the stock's technical indicators point to potential overbought conditions. Despite these concerns, the company's financial stability and positive cash flow are strengths.

Positive Factors

Operating cash flow & free cash flow growth

Consistently strong operating cash flow and growing free cash flow provide durable internal funding for maintenance capex, network expansion and debt servicing. This strengthens liquidity and reduces reliance on external financing, supporting stable operations and strategic investments over months.

Strong profitability and equity efficiency

Robust gross and improving net margins alongside strong ROE indicate the company converts revenue into shareholder returns efficiently. Margin resilience and equity efficiency underpin sustainable earnings generation and fund reinvestment, benefiting long-term operational scalability.

Diversified multi‑service network across India & GCC

A diversified footprint of hospitals, clinics, diagnostics and pharmacies across India and GCC spreads revenue sources and reduces market-specific risk. Integrated care and retail pharmacy capture patient lifetime value and referral flows, supporting durable demand and cross‑sell opportunities.

Negative Factors

Revenue volatility and recent decline

Volatile top-line performance and a recent revenue decline complicate capacity planning, margin leverage and multi‑year growth forecasting. Persistent variability can weaken negotiating power with payers and corporates and hinder predictable capital allocation over the coming quarters.

Severe EPS contraction

A near‑100% drop in EPS signals significant earnings disruption, whether from one-offs or operational pressures. Such earnings volatility undermines reinvestment capacity, raises stakeholder uncertainty, and can constrain medium‑term strategic initiatives until profitability normalizes.

Moderate leverage and high total liabilities

Moderate leverage with elevated total liabilities limits financial flexibility for capex, acquisitions or downturns. If cash generation weakens, servicing liabilities could force slower investment or costly refinancing, increasing structural risk over the next several quarters.

Aster DM Healthcare Ltd. Business Overview & Revenue Model

Company Description

Aster DM Healthcare Limited operates as a healthcare company in India and internationally. The company operates through Hospitals, Clinics, Retail Pharmacies, and Other segments. It provides primary, secondary, tertiary, and quaternary healthcare services through 29 hospitals, 120 clinics, 371 retail pharmacies, 114 labs, and patient experience centers under the Aster, Medcare, and Access brands. In addition, it offers healthcare retailing, diagnostic laboratories, digital health, and medical education services. The company was founded in 1987 and is headquartered in Dubai, the United Arab Emirates.

How the Company Makes Money

Aster DM Healthcare makes money primarily by charging for healthcare services delivered through its facilities and by selling healthcare-related products through its pharmacy network. Key revenue streams typically include: (1) Hospital services (inpatient and outpatient): Revenue is generated from patient admissions, bed/room charges, operating theatre and procedure fees, intensive/critical care services, nursing and other facility charges, and medical packages. Higher-acuity and specialized procedures (e.g., surgeries and interventional treatments) generally command higher billing and can contribute materially to revenue mix where available in the network. (2) Diagnostics and allied services: The company earns fees from laboratory testing, pathology, radiology and imaging (e.g., X-ray/CT/MRI/ultrasound where offered), and other diagnostic procedures. These services generate revenue both from hospital inpatients/outpatients and from walk-in or referral patients, depending on the site. (3) Clinics and consultation services: Revenue is generated through outpatient consultations, minor procedures, preventive health checks, and follow-up care provided in clinics and outpatient departments. (4) Pharmacy/retail: The company earns revenue from the sale of prescription medicines and over-the-counter healthcare products via its pharmacies, benefiting from patient footfall within hospitals and surrounding communities. (5) Payer/channel mix and settlement: Payments may come from self-pay patients, corporate/employee health arrangements, and government or private insurance/TPA (third-party administrator) reimbursements; earnings depend on volumes, negotiated rates, case mix, and reimbursement terms. Significant factors that can influence overall earnings include patient volumes and occupancy, the mix of specialties and complexity of cases, pricing and reimbursement rates with insurers/TPAs and corporate accounts, and the contribution of pharmacy and diagnostics attached to hospital/clinic traffic. Specific material partnerships or payer contracts are not provided here because they are not available in the prompt (null).

Aster DM Healthcare Ltd. Financial Statement Overview

Summary

Aster DM Healthcare Ltd. demonstrates a solid financial position with strong profitability and effective equity utilization. While revenue growth and profit margins reflect operational strengths, volatility in financial performance suggests potential risks. The balance sheet shows moderate leverage, and cash flow stability is a positive aspect, though there are areas for improvement in cash flow consistency.

Income Statement

Aster DM Healthcare Ltd. shows a strong gross profit margin, indicating efficient cost management. The net profit margin has improved significantly, driven by a sharp increase in net income. Revenue growth has been volatile, with a decline in the latest period after prior growth, suggesting some instability. EBITDA and EBIT margins are healthy but have shown fluctuations, reflecting operational efficiency with room for improvement.

Balance Sheet

The balance sheet presents a moderate debt-to-equity ratio, which suggests a balanced approach to leveraging. However, the equity ratio indicates a moderate level of equity financing. ROE is strong, reflecting effective use of shareholders' equity. Despite positive aspects, the high total liabilities suggest potential financial risk if not managed carefully.

Cash Flow

Cash flow analysis reveals a strong operating cash flow, which is a positive sign for liquidity. Free cash flow has shown growth, enhancing the company's ability to fund operations and investments. However, the free cash flow to net income ratio suggests some inconsistency, indicating potential volatility in cash generation relative to earnings.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	43.25B	41.38B	36.99B	29.94B	102.53B	86.08B
Gross Profit	20.81B	22.92B	19.76B	15.59B	36.67B	29.06B
EBITDA	8.33B	7.06B	5.33B	4.10B	12.11B	8.07B
Net Income	3.31B	53.78B	1.29B	4.25B	5.26B	1.48B
Balance Sheet
Total Assets	78.08B	66.06B	179.91B	148.81B	125.46B	116.43B
Cash, Cash Equivalents and Short-Term Investments	12.76B	13.81B	1.11B	3.96B	3.69B	3.06B
Total Debt	20.89B	20.18B	13.84B	57.00B	49.07B	48.04B
Total Liabilities	30.37B	29.55B	129.61B	100.21B	80.64B	78.09B
Stockholders Equity	45.33B	34.28B	45.60B	44.48B	39.53B	33.72B
Cash Flow
Free Cash Flow	873.00M	790.10M	-6.39B	9.86B	7.65B	11.45B
Operating Cash Flow	3.19B	4.25B	1.58B	18.34B	13.13B	15.69B
Investing Cash Flow	-747.80M	60.15B	-8.85B	-9.72B	-5.70B	-3.30B
Financing Cash Flow	-2.14B	-63.58B	10.53B	-8.17B	-6.85B	-11.16B

Aster DM Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 615.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTERDM, the sentiment is Neutral. The current price of 615.2 is below the 20-day moving average (MA) of 654.58, above the 50-day MA of 611.70, and below the 200-day MA of 623.11, indicating a neutral trend. The MACD of 10.24 indicates Positive momentum. The RSI at 45.26 is Neutral, neither overbought nor oversold. The STOCH value of 19.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ASTERDM.

Aster DM Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AJANTPHARM	72 Outperform	₹362.84B	31.59	―	1.04%	10.74%	11.91%
NH	71 Outperform	₹337.77B	75.82	―	0.24%	14.72%	8.37%
KIMS	65 Neutral	₹258.93B	114.01	―	―	25.74%	1.41%
MEDANTA	65 Neutral	₹270.13B	83.79	―	0.04%	15.78%	15.01%
GLAND	63 Neutral	₹267.76B	27.13	―	1.07%	-1.51%	14.27%
ASTERDM	62 Neutral	₹324.99B	151.95	―	0.84%	-36.14%	-93.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Aster DM Healthcare Ltd. Corporate Events

Aster DM Healthcare Seeks Shareholder Nod via E-Voting on Director Appointment and Loan Powers

Aster DM Healthcare has initiated a postal ballot process to seek shareholder approval for key corporate actions, including the appointment of Dr. Mandayapurath Azad Moopen as an Executive Director and authorization to grant loans, guarantees, or securities under Section 185 of the Companies Act, 2013. The company is conducting the vote entirely through electronic means in line with regulatory guidance, with e-voting open between March 14 and April 12, 2026, and results to be announced by April 14, signalling continued adherence to governance norms and active shareholder engagement in its leadership and financing decisions.

Aster DM Wins Strong Vote for QCIL Merger, Set to Form Top-Three Hospital Chain

Aster DM Healthcare has secured strong stakeholder backing for its planned amalgamation with Quality Care India Ltd., winning 96.68% shareholder approval, including a significant majority of minority shareholders, as well as support from unsecured creditors. The deal, which has already cleared competition and stock exchange review and now awaits remaining NCLT approvals, will create Aster DM Quality Care Ltd., expected to rank among India’s top three hospital chains with 39 hospitals and more than 10,625 beds across nine states and 28 cities, materially scaling the group’s nationwide footprint, workforce and patient reach.

Aster DM Healthcare Shareholders Clear Amalgamation with Quality Care India

Aster DM Healthcare Ltd. operates hospitals and other medical facilities, offering a range of healthcare services to patients in India and beyond, and its shares are listed on both BSE and NSE, giving it access to a wide base of public investors. The company focuses on expanding and structuring its operations through corporate actions overseen by Indian regulatory and judicial authorities.

Aster DM Healthcare has disclosed that its equity shareholders have approved a Scheme of Amalgamation with Quality Care India Ltd., following a court-convened meeting ordered by the National Company Law Tribunal in Hyderabad. The scheme, cleared by the requisite majority of overall and public shareholders via remote and electronic voting, marks a key step in integrating Quality Care India into Aster DM Healthcare’s structure, subject to completion of remaining regulatory and tribunal processes.

The approval of the amalgamation scheme indicates strong shareholder support for the proposed corporate restructuring, which is expected to streamline group operations and could enhance Aster DM Healthcare’s scale and efficiency in the healthcare market. Compliance with Companies Act and SEBI disclosure norms, along with publication of voting results and the scrutinizer’s report on the company’s website, underlines Aster DM’s adherence to governance standards and provides transparency for investors and other stakeholders.

Aster DM Healthcare’s creditors clear key vote on amalgamation plan

Aster DM Healthcare said its unsecured trade creditors have approved a proposed Scheme of Amalgamation between Quality Care India Ltd. and Aster DM Healthcare Ltd., as directed by the National Company Law Tribunal, Hyderabad Bench. The resolution was passed by the requisite majority of creditors, representing at least three-fourths in value, through remote e-voting and e-voting at a virtual meeting.

The company has published the detailed voting results and the scrutinizer’s consolidated report on its website, in line with SEBI’s listing and disclosure requirements and the Companies Act. Creditor approval marks a key procedural step in the amalgamation process, strengthening the legal and regulatory pathway for the merger and signaling creditor support for the group’s planned corporate restructuring.

Aster DM Healthcare Releases Latest Investor Presentation on Company Performance

Aster DM Healthcare Ltd. has released an investor presentation detailing the company’s recent performance to the stock exchanges in Mumbai. The disclosure signals ongoing engagement with shareholders and the broader market, providing investors with updated insights into the company’s operations and financial standing, although the specific contents of the presentation are not included in the announcement.

Aster DM Healthcare Clears Q3 FY26 Results, New ESOP and Internal Capital Restructuring

Aster DM Healthcare Ltd.’s board has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with the statutory auditor issuing an unmodified opinion, underscoring the integrity of the company’s reported performance. The board also cleared a new Employee Stock Option Scheme 2026 for eligible staff across the company, its unlisted subsidiaries and its unlisted holding company, a move aimed at strengthening employee alignment and retention, and approved the conversion of a ₹129.35 crore inter-corporate loan into equity in wholly owned unit Aster DM Multispecialty Hospital Pvt. Ltd., reinforcing its capital structure without altering ownership or control. Additionally, directors authorised the company to extend loans, guarantees and securities to group entities within legal limits and approved shifting the maintenance of statutory registers and returns to its Bengaluru corporate office, with shareholder approval for the ESOP, intra-group financing flexibility and records relocation to be sought via postal ballot.

Aster DM Healthcare Moves to Fully Acquire MIMS, Lifts Stake Toward 100%

Aster DM Healthcare’s Investment and Finance Committee has approved a proposal to increase its stake in its material subsidiary, Malabar Institute of Medical Sciences Ltd. (MIMS), from 79.75% to 100% by acquiring up to an additional 20.25% equity from existing shareholders for cash consideration. The move, which is not classified as a related-party transaction and requires no specific regulatory approvals, will be executed through a letter of offer expected to be dispatched shortly, with completion targeted within three months thereafter, and is aimed at fully consolidating a highly profitable hospital asset within Aster’s portfolio, potentially enhancing control, earnings consolidation and strategic flexibility for the group.

Aster DM Healthcare Plans Investor and Analyst Hospital Visits in Kerala

Aster DM Healthcare Limited has scheduled a hospital visit for a group of investors and analysts to its Aster Medcity facility in Kochi and QCIL KIMS in Trivandrum on January 8 and 9, 2026, which will include interactions with the company’s management. The company has clarified that the schedule may change due to exigencies and that no unpublished price-sensitive information will be shared during these interactions, underscoring its intent to enhance transparency and engagement with the financial community while remaining compliant with disclosure regulations.

Aster DM Healthcare Moves to Full Ownership of Prerana Hospital

Aster DM Healthcare has increased its stake in subsidiary Prerana Hospital Limited from 87% to 98.92% through a cash acquisition of an additional 11.94% equity for INR 38.36 crore, with the remaining 1.08% slated to be acquired by December 31, 2026, at which point Prerana will become a wholly owned subsidiary. The move, which does not involve any related-party transactions and requires no regulatory approvals, underscores Aster DM Healthcare’s strategy of consolidating full control over its hospital assets, potentially streamlining decision-making, improving operational integration, and enhancing its presence in the healthcare market through the fully owned Prerana Hospital business.